MicroRNAs (miRNAs) are believed to have fundamental roles in tumorigenesis and have great potential for the diagnosis and treatment of cancer. However, the roles of miRNAs in hepatocellular carcinogenesis are still not fully elucidated. We investigated the aberrantly expressed miRNAs involved in hepatoma by comparison of miRNA expression profiles in cancerous hepatocytes with normal primary human hepatocytes, and 37 dysregulated miRNAs were screened out by twofold change with a significant difference (Po0.05). Clustering analysis based on 13 miRNAs with changes over 15-folds showed that the miRNA expression patterns between the cancerous and normal hepatocytes were clearly different. Among the 13 miRNAs, we found that miR-375 was significantly downregulated in hepatocellular carcinoma (HCC) tissues and cell lines. Overexpression of miR-375 in liver cancer cells decreased cell proliferation, clonogenicity, migration/ invasion and also induced G1 arrest and apoptosis. To unveil the molecular mechanism of miR-375-mediated phenotype in hepatoma cells described above, we examined the putative targets using bioinformatics tools and found that astrocyte elevated gene-1 (AEG-1) was a potential target of miR-375. Then we demonstrated that miR-375 bound directly to the 3 0 -untranslated region of AEG-1 and inhibited the expression of AEG-1. TaqMan quantitative reverse transcriptase-PCR and western blot analysis showed that miR-375 expression was inversely correlated with AEG-1 expression in HCC tissues. Knockdown of AEG-1 by RNAi in HCC cells, similar to miR-375 overexpression, suppressed tumor properties. Ectopic expression of AEG-1, conversely, could partially reverse the antitumor effects of miR-375. In a mouse model, therapeutic administration of cholesterol-conjugated 2 0 -O-methyl-modified miR-375 mimics (Chol-miR-375) could significantly suppress the growth of hepatoma xenografts in nude mice. In conclusion, our findings indicate that miR-375 targets AEG-1 in HCC and suppresses liver cancer cell growth in vitro and in vivo, and highlight the therapeutic potential of miR-375 in HCC treatment.
MicroRNAs (miRNAs) are believed to have fundamental roles in tumorigenesis and have great potential for the diagnosis and treatment of cancer. However, the roles of miRNAs in hepatocellular carcinogenesis are still not fully elucidated. We investigated the aberrantly expressed miRNAs involved in hepatoma by comparison of miRNA expression profiles in cancerous hepatocytes with normal primary human hepatocytes, and 37 dysregulated miRNAs were screened out by twofold change with a significant difference (Po0.05). Clustering analysis based on 13 miRNAs with changes over 15-folds showed that the miRNA expression patterns between the cancerous and normal hepatocytes were clearly different. Among the 13 miRNAs, we found that miR-375 was significantly downregulated in hepatocellular carcinoma (HCC) tissues and cell lines. Overexpression of miR-375 in liver cancer cells decreased cell proliferation, clonogenicity, migration/ invasion and also induced G1 arrest and apoptosis. To unveil the molecular mechanism of miR-375-mediated phenotype in hepatoma cells described above, we examined the putative targets using bioinformatics tools and found that astrocyte elevated gene-1 (AEG-1) was a potential target of miR-375. Then we demonstrated that miR-375 bound directly to the 3 0 -untranslated region of AEG-1 and inhibited the expression of AEG-1. TaqMan quantitative reverse transcriptase-PCR and western blot analysis showed that miR-375 expression was inversely correlated with AEG-1 expression in HCC tissues. Knockdown of AEG-1 by RNAi in HCC cells, similar to miR-375 overexpression, suppressed tumor properties. Ectopic expression of AEG-1, conversely, could partially reverse the antitumor effects of miR-375. In a mouse model, therapeutic administration of cholesterol-conjugated 2 0 -O-methyl-modified miR-375 mimics (Chol-miR-375) could significantly suppress the growth of hepatoma xenografts in nude mice. In conclusion, our findings indicate that miR-375 targets AEG-1 in HCC and suppresses liver cancer cell growth in vitro and in vivo,
Introduction
Hepatocellular carcinoma (HCC) is a worldwide malignancy with no ideally targeted therapies. Studies aimed at the definition of the mechanisms associated with hepatocarcinogenesis, identification of novel diagnostic biomarkers and development of effective therapeutic interventions for HCC are urgently needed (Santamaria et al., 2007) .
MicroRNAs (miRNAs) are small noncoding RNAs that are believed to have fundamental roles in carcinogenesis. Due to the imperfect complement for targeting mRNA transcripts, a miRNA can posttranscriptionally regulate multiple target genes and thus functions as a molecular 'rheostat' (Baek et al., 2008) . Alterations in miRNA expression can modulate key cellular processes involved in tumorigenesis, and evaluation of changes in miRNA expression could provide insight into basic mechanisms of tumor formation and progression (Braconi and Patel, 2008) . The expression patterns of miRNAs appear to be tissue-specific and are more accurate than mRNA-based profiling in cancer diagnosis (Lu et al., 2005) . Furthermore, therapeutic modulation of an miRNA may affect multiple target genes simultaneously to achieve excellent clinical benefits (Kota et al., 2009) . Therefore, miRNAs may have great potential in the diagnosis and treatment of cancers. Over the past few years, several studies have reported some important aberrant miRNA expression profiles in HCC tissues compared with matched nonmalignant tissues, and found multiple specific dysregulated miRNAs associating with the development of HCC (Murakami et al., 2006; Gramantieri et al., 2007; Meng et al., 2007; Budhu et al., 2008; Huang et al., 2008; Jiang et al., 2008; Ladeiro et al., 2008; Varnholt et al., 2008) . However, the roles of dysregulated miRNAs in HCC are still not fully elucidated.
As a relatively novel gene, astrocyte elevated gene-1 (AEG-1) has emerged as an important oncogene in multiple aspects of cancer development and progression (Hu et al., 2009) . Overexpression of AEG-1 was observed in melanoma (Kang et al., 2005) , glioma (Kang et al., 2005) , neuroblastoma (Lee et al., 2009) , and carcinomas of breast (Li et al., 2008) , prostate (Kikuno et al., 2007) , esophagus (Yu et al., 2009 ), stomach (Jian-bo et al., 2011 and liver (Yoo et al., 2009) , which was correlated with poor clinical outcomes. It was reported that AEG-1 was overexpressed in 490% of human HCC compared with normal liver and had a central role in regulating diverse aspects of HCC pathogenesis (Yoo et al., 2009) . However, the mechanism of upregulation of AEG-1 has not yet been fully clarified.
Interestingly, AEG-1 is a putative target of miR-375 as predicated by TargetScan (an online software provided by MIT for prediction of miRNA targets, http://www.target scan.org/). MiR-375 was reported originally to be an isletspecific miRNA and regulate insulin secretion (Poy et al., 2004) . However, reduced expression of miR-375 was found in pancreatic cancer , and carcinomas of head and neck (Avissar et al., 2009) , stomach (Tsukamoto et al., 2010) and liver (Ladeiro et al., 2008; Liu et al., 2010) . MiR-375 could negatively regulate PDK1 and 14-3-3z in gastric carcinomas, reduce the viability and induce apoptosis of gastric carcinoma cells (Tsukamoto et al., 2010) . As to liver cancer, miR-375 has been reported to be downregulated in HCC tissues and target yes-associated protein (YAP) . Liu et al. (2010) found that miR-375 could inhibit proliferation and invasion of HCC cells in vitro by MTT and wound-healing assay. However, the functions and mechanisms of miR-375 involved in HCC are not fully elucidated and the therapeutic application of miR-375 has not been reported.
In this report, we identified a specific aberrant miRNA expression profiling in HCC by comparison of miRNA expression profiles in cancerous hepatocytes with normal primary human hepatocytes. We further investigated miR-375, one of the most downregulated miRNAs, to explore its functions and mechanisms in hepatic carcinogenesis. We demonstrated that miR-375 targeted oncogene AEG-1 in HCC and reexpression of miR-375 suppressed liver cancer cell growth in vitro and in vivo.
Results

MiRNAs expressed differentially between cancerous and normal hepatocytes
The expression profiles containing 723 human miRNAs were determined in seven hepatoma cell lines and three cases of normal primary human hepatocytes (PHHC) using human miRNA array (Agilent, Santa Clara, CA, USA). The microarray data were deposited in NCBI's Gene Expression Omnibus (GEO) public database (http://www.ncbi.nlm.nih.gov/geo/, Gene Expression Omnibus accession number, GSE20077). MiRNA expressions of cancerous hepatocytes were compared with those of normal hepatocytes and 37 dysregulated miRNAs were screened out by twofold change with a significant difference (Po0.05). As shown in Table 1 , there were nine upregulated miRNAs and 28 downregulated miRNAs in HCC, of which, miR-221 and miR-99b were the most overexpressed miRNAs, whereas miR-375, miR-192, miR-146b-5p, miR-885-5p, miR-122* and miR-122 were noted for their greatest changes of decreased expression. A total of 13 miRNAs with changes over 15-folds were analyzed by clustering, which exhibited significantly differential expression pattern between the cancerous and normal hepatocytes ( Figure 1A) . To verify the microarray data, TaqMan quantitative reverse transcriptase-PCR (qRT-PCR) was applied to quantify miR-221 and miR-375 expression in hepatoma cell lines and PHHC ( Figure 1B ). The result of microarray exhibited a good consistency with TaqMan qRT-PCR ( Figure 1C ). These aberrantly expressed miRNAs may provide insights into pathogenesis of HCC, and thus may be used for diagnosis.
MiR-375 is downregulated in HCC Among downregulated miRNAs, miR-375 arose our interest as it was predicated to target AEG-1, which has important roles in hepatocarcinogenesis (Yoo et al., 2009) . We found that miR-375 was significantly downregulated in seven hepatoma cell lines compared with normal hepatocytes (Figure 1 ). Next, we detected miR-375 expression in additional 60 pairs of HCC and matched adjacent nontumor tissues, and found that miR-375 was also significantly suppressed in HCC tissues (Figure 2a) . Interestingly, the abundance of miR-375 was inversely correlated with that of AEG-1 (Figures 2b and c) , a potential target of miR-375. However, there was no significant correlation between miR-375 and other clinicopathological features.
MiR-375 decreases liver cancer cell growth, invasion, and induces G1 arrest and apoptosis To explore the role of miR-375 in HCC, the hepatoma cell lines were transfected with miR-375 precursor (premiR-375) and further used for functional analysis. For optimization of transfection conditions, Cy3-labeled pre-miR-NC (negative control) transfection confirmed that a high efficiency of transfection (about 90%) could be obtained at the concentration of 100 nM without obvious toxicity (Supplementary Figure S2) . Unless noted otherwise, all miRNAs were transfected at the concentration of 100 nM. As shown in Figure 3A , the significant increase in miR-375 expression could be verified by TaqMan qRT-PCR in hepatoma cell lines transfected with pre-miR-375.
Sustained cell growth is a distinctive hallmark of cancer. Overexpression of miR-375 could markedly suppress the proliferation of hepatoma cell lines ( Figure 3B ), increase the percentages of cells in G1 phase and decrease the cell percentages in S phase by nearly 10% ( Figure 3C ). Evading apoptosis is another superiority of tumor cells for limitless growth. Analysis of apoptosis showed that the numbers of apoptotic cells were conspicuously increased in HepG2 cells transfected with miR-375 ( Figure 3D ). Morphological changes of apoptosis by DAPI (4 0 ,6-diamidino-2-phenylindole) staining confirmed this result (Supplementary Figure S3) . To assess the functional role of miR-375 in tumor formation, the colony formation and anchorageindependent growth were measured in HepG2 cells. Analysis of clonogenicity showed that miR-375-transfected cells displayed much fewer and smaller colonies than control transfectants ( Figure 3E ). Transwell insert chambers were introduced to investigate the impact of miR-375 on cell motility. As shown in Figure 3F , enhancing miR-375 expression could effectively suppress HepG2 cell migration and invasion. These data indicated that miR-375 functioned as a tumor suppressor in HCC.
MiR-375 targets AEG-1, and AEG-1 is involved in the antitumor effects of miR-375 To elucidate the antitumor effects of miR-375 in HCC, we further exploited miR-375's targets. Interestingly, AEG-1 is a putative target of miR-375 ( Figure 4a ). Luciferase assay indicated that miR-375 could directly aim at its predicted binding site of AEG-1 and lead to the suppression of luciferase expression of pLUC-AEG-1, whereas miR-375 had no obvious effects on its control pLUC-mutAEG-1 (Figure 4b ). Overexpression of miR-375 in HepG2 cells greatly reduced the mRNA and protein level of AEG-1 (Figures 4c and e) , whereas inhibition of miR-375 in normal PHHC cells enhanced AEG-1 mRNA and protein expression (Figures 4d and f). Moreover, miR-375 was significantly downregulated whereas AEG-1 was upregulated in HCC tissues, and a significant inverse correlation was found between miR-375 and AEG-1 expression ( Figure 2 ).
To confirm AEG-1 is involved in the antitumor effects of miR-375, we first silenced AEG-1 expression by RNAi in HepG2 cells (Supplementary Figure S4) . As shown in Supplementary Figure S5 , specific knockdown of AEG-1 by RNAi inhibited HepG2 cell proliferation, clonogenicity, migration/invasion, and also induced G1 arrest and apoptosis, which phenocopied the effects of miR-375 in HepG2 cells. Next, we examined whether the restoration of AEG-1 could rescue the antitumor effects of miR-375. Co-transfection of pcDNA3.1-AEG-1 and pre-miR-375 in HepG2 cells efficiently restored AEG-1 expression with enhanced expression of miR-375, and partially reversed the antitumor effects induced by miR-375 ( Figure 5 ). These results suggested that miR-375 suppressed AEG-1 expression by binding directly to the 3 0 -UTR of AEG-1, and the negative regulation of AEG-1 by miR-375 might contribute partially to antitumor effects of miR-375 involved in HCC.
MiR-375 inhibits tumor growth of hepatoma xenografts in nude mice
Considering the important roles of miR-375 in HCC, potentially therapeutic use of miR-375 attracted our attention. As miR-375 is significantly downregulated in HCC, cholesterol-conjugated 2 0 -O-methyl-modified miR-375 mimics (Chol-miR-375) was prepared for replacement therapy. This chemically stabilized miRNAs might have markedly improved pharmacological properties as described before (Soutschek et al., 2004; Petri et al., 2009) . We demonstrated that Cy3-labeled cholesterol-conjugated miRNA mimics could efficiently enter SK-HEP-1 and HepG2 cells without transfection reagents or electroporation ( Figure 6A ), and Chol-miR-375 could significantly increase the expression of miR-375 (Supplementary Figure S6A) . Subcutaneous hepatoma xenografts were established in the flanks of athymic nude mice using HepG2 cells. Intratumor injection with Chol-miR-375 could significantly inhibit the growth of tumor ( Figure 6B ): the growth curves of Chol-miR-375 and Chol-miR-NC-treated tumors became divergent on day 16 and the average fold increase of tumor volumes at the sacrifice with respect to the first measurements in Chol-mir-375-treated tumors was much smaller than that in control tumors (6.81 ± 1.44 vs 11.89 ± 2.62, P ¼ 0.039).
To clarify the cellular mechanisms underlying miR-375-mediated tumor suppression, resected tissues from those treated xenograft tumors were analyzed to verify miR-375 and AEG-1 expression, and measured for mitotic index and expression of Ki67 as markers of proliferation. At the end of the experiment, Chol-miR-375 could significantly increase the expression of miR-375 (Supplementary Figure S6B) and decrease the expression of AEG-1 ( Figure 6E ) in vivo. Consistent with the above results, hematoxylin and eosin and Ki67 staining revealed markedly reduced proliferation index in Chol-miR-375-treated tumors ( Figure 6C and D) . All these data indicated that reexpression of miR-375 could inhibit liver cancer cell growth in vivo.
Discussion
In this study, we identified the aberrantly expressed miRNAs involved in HCC through the comparison of miRNA expression profiles in cancerous hepatocytes with that in normal primary human hepatocytes and found 37 dysregulated miRNAs (Table 1) . Although several researches have reported multiple aberrant miRNA expression profiles in HCC tissues, the results from different research teams are lack of consistency (Gramantieri et al., 2008) . Besides the variations of technological methodologies and sample origin, one main reason for this inconsistency is possibly that the liver is a structurally and functionally heterogeneous organ consisting of different types of cells, including hepatocytes (parenchymal cells), Kupffer cells, Stellate cells, bile duct cells, fibroblasts and inflammatory cells (Malarkey et al., 2005) . HCC samples from patients with different etiologies usually have different cell activities and cell proportions, which may result in artifact of miRNA profiles. In our study, however, we discovered many dysregulated miRNAs in HCC that were consistently reported before (such as miR-221, miR-122, miR-101, miR-194, miR-195 and miR-375 , and so on). Hence, using cancerous and normal hepatocytes instead of whole liver tissues to screen the dysregulated miRNAs may assist us to find 'cancer cell-specific' miRNA expression profiles.
We found that miR-375 was significantly downregulated in liver cancer cell lines and HCC tissues (Figures 1 and 2a) . These results are in agreement with those recently reported . We also demonstrated that overexpression of miR-375 in liver cancer cells decreased cell proliferation, clonogenicity, migration/invasion, and also induced G1 arrest and apoptosis (Figure 3 ). The observations that ectopic expression of miR-375 inhibited proliferation and invasion of liver cancer cells are also identical to the results published by Liu et al. through MTT and woundhealing assay . That the ectopic expression of miR-375 induced apoptosis in liver cancer cells is similar to the phenomenon observed in gastric carcinoma cells (Tsukamoto et al., 2010) . To our best knowledge, however, our observations that miR-375 could decrease clonogenic ability and induce G1 arrest of liver cancer cells have not been reported before. Therefore, our data provided a more comprehensive understanding of the tumor suppressor role of miR-375 during HCC development.
Previous studies have demonstrated that AEG-1 is overexpressed in multiple types of cancers and augments cell proliferation, colony formation, invasion, metastasis and chemoresistance (Emdad et al., 2007; Hu et al., 2009) . AEG-1 functions as a downstream mediator of the transforming activity of oncogenic Ha-Ras and c-Myc, and AEG-1 overexpression activates the PI3K/Akt, MicroRNA-375 targets oncogene AEG-1 in liver cancer X-X He et al NFkB and Wnt/b-catenin signaling pathways (Lee et al., 2006 (Lee et al., , 2009 Yoo et al., 2008 Yoo et al., , 2009 ). Here, we demonstrated that miR-375 suppressed AEG-1 expression by binding directly to the 3 0 -UTR of AEG-1 (Figure 4) , and inverse correlation was observed between miR-375 and AEG-1 expression in HCC tissues ( Figure 2) . We showed that AEG-1 was upregulated in HCC tissues and silencing of AEG-1 by RNAi inhibited tumor properties of liver cancer cells resembling that of miR-375 overexpression (Figure 2b and Supplementary Figure S5) . Moreover, restoration of AEG-1 could partially reverse the antitumor effects induced by miR-375 ( Figure 5 ). Therefore, upregulation of AEG-1 in HCC because of miR-375 deprivation may, at least partially, explain the antitumor effects of miR-375 involved in HCC. MiR-375 is also reported to target YAP in HCC , PDK1 and 14-3-3z in gastric carcinomas (Tsukamoto et al., 2010) . In a word, the reported targets of miR-375 and our observations indicated that miR-375 might regulate multiple signaling pathways, and loss of miR-375 would lead to the tumor progression in HCC. Anticancer therapy of HCC remains a major clinical challenge and HCC is often diagnosed at an advanced stage when it is no longer eligible for surgical resection or liver transplantation. The above evidence underscores the possibility of miR-375 as a novel target for therapeutic intervention. Our animal studies indicated that Chol-miR-375 treatment could suppress the growth of hepatoma xenografts in nude mice and decrease the expression of AEG-1 in treated tumors (Figure 6 ). The studies in vivo support our observations that miR-375 targets AEG-1 and suppresses liver cancer cell growth in vitro. Similarly, Kota et al. (2009) proved that replacement therapy with adenovirus-associated virus (AAV)-mediated miR-26a resulted in the inhibition of cancer cell proliferation and provided dramatic protection from disease progression without obvious toxicity in a murine liver cancer model (Kota et al., 2009) . Furthermore, miRNAs are natural antisense interactors and their small size (23-24 nucleotides in length) makes them very attractive for drug development (Tili et al., 2007) . Therefore, systemic administration of miR-375 delivered by cholesterolconjugated 2 0 -O-methyl-modified oligonucleotides, lentivirus vector (Scherr et al., 2007) , AAV vectors (Kota et al., 2009) , or locked nucleic acid-modified oligonucleotides (Vester and Wengel, 2004 ) is worthy to be further determined for the anticancer treatment of HCC.
In conclusion, this study indicates that miR-375 negatively regulates oncogene AEG-1 and inhibits liver cancer cell growth in vitro and in vivo. Our findings also highlight the therapeutic potential of miR-375 in HCC treatment and support the development of effective therapeutic strategies that target miR-375 (or its targets such as AEG-1 and YAP) by a genetic or pharmacological approach.
Materials and methods
Cell lines and patient samples
The hepatoma cell lines SK-HEP-1, HepG2, Hep3B, Huh7, MHCC97-H and MHCC97-L (Li et al., 2004) , and SMMC-7721 were cultured and maintained in Dulbecco's modified Eagle medium supplemented with 100 ml/l fetal bovine serum, 100 IU/ml penicillin and 100 mg/ml streptomycin at 37 1C with 5% CO 2 . Following ethical and institutional guidelines and after informed consent of the tissue donors, samples (including 60 pairs of HCC and adjacent nontumor tissues) were collected from 60 HCC patients undergoing partial hepatectomy and immediately stored in RNAlater (Ambion, Austin, TX, USA). The characteristics of these patients are described in Supplementary Table S1 . Normal PHHC were isolated using a modified four-step retrograde perfusion technique as reported previously (Maruyama et al., 2003; Meng et al., 2010) . Cell morphologies of PHHC and hepatoma cell lines used in this study are shown in Supplementary Figure S1 . The study was approved by the local Research Ethics Committee at the Tongji Hospital of Huazhong University of Science and Technology.
RNA and protein extraction
The mirVana PARIS Kit (Ambion) was applied to isolate total RNA and protein from the same experimental samples.
MiRNA microarray analysis
Total RNA (100 ng) were labeled using the Agilent miRNA labeling reagent and hybridized to Agilent human miRNA array (V2). Images were scanned with the Agilent microarray scanner and the results were obtained by Agilent feature extraction software. Finally, the raw intensity data were further analyzed using GeneSpring10.0 software (Agilent).
TaqMan qRT-PCR
The expression of mature miRNAs was assayed using the TaqMan MicroRNA Assays (Applied Biosystems, Foster City, CA, USA) specific for hsa-miR-221 and hsa-miR-375. Reverse transcription reaction was done using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) and followed by real-time PCR using TaqMan Gene Expression Master Mix (Applied Biosystems) on Applied Biosystems 7900HT Fast Real-Time PCR System according to the manufacturer's instruction. RUN6B RNA was used as a control.
MiR-375 precursor/inhibitor, plasmid, siRNA and cell transfection Stability-enhanced miR-375 precursor (pre-miR-375), miR-375 inhibitor (anti-miR-375) and their matched NC (pre-miR-NC and anti-miR-NC) were from Ambion. AEG-1 (also known as MTDH) expressing vector pcDNA3.1-AEG-1 (lacking 3 0 -UTR of AEG-1), the control and AEG-1 siRNAs were prepared as previously described (Lee et al., 2006; Zhang et al., 2011) . Cell transfections were performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction.
Cell proliferation assay Cells (5000 per well) were plated in 96-well plates and incubated at 37 1C. Cell proliferation was assessed at 24 h, 48 h and 72 h after transfection using the CellTiter 96 AQueous One Solution Cell Proliferation assay kit (Promega, Madison, WI, USA).
Flow cytometry analysis of cell cycle and apoptosis For cell-cycle analysis, cells were seeded in 6-well plates. At 72 h after transfection, cells were collected and fixed in 70% ethanol at 4 1C overnight. After having washed and resuspended in 100 ml phosphate-buffered saline, fixed cells were treated with 50 ml RNase (50 mg/ml) in 37 1C for 30 min and stained with 200 ml Propidium Iodide (KeyGen Biotech. Co. Ltd., Nanjing, China) in 4 1C for 30 min. Cell-cycle analysis was performed using a FACSAria cell sorting system (BD Biosciences, San Jose, CA, USA). For apoptosis analysis, cells seeded in 24-well plates were harvested 72 h after transfection and processed with Annexin V-fluorescein isothiocyanate/ Propidium Iodide kit (KeyGen Biotech) according to the manufacturer's instructions.
Cell migration and invasion assay
The migration and invasion assay was performed by using Transwell insert chambers (6.5 mm. in diameter, 8 mm pore size, Corning, USA). For migration assay, 2 Â 10 5 HepG2 transfected cells were placed into the upper chamber in serumfree medium in triplicate 12 h after transfection. The lower chamber was filled with 600 ml Dulbecco's modified Eagle medium with 10% fetal bovine serum as chemoattractant.
After incubation for 24 h at 37 1C in a 5% CO 2 humidified incubator, nonmigrating cells in the upper chambers were removed by using a cotton swab, and cells migrated to the lower surface of membrane were fixed with methanol and stained with 0.1% crystal violet. Migrating cells were scored by counting at least six fields per membrane under a light microscope. The invasion activity was assayed by seeding 2 Â 10 5 transfectants in serum-free medium in triplicate on transwell polycarbonate membrane inserts precoated with a layer of diluted basement membrane Matrigel (ECM gel, Sigma, St Louis, MO, USA). 600 ml Dulbecco's modified Eagle medium with 10% fetal bovine serum as chemoattractant were added to the lower chamber. After 24 h incubation, noninvading cells were removed with cotton swabs and invasive cells were fixed, stained and counted as described above.
Analysis of clonogenicity in vitro
For colony formation analysis, 24 h after transfection, 100 viable HepG2 transfectants were placed in 24-well plates and maintained in complete medium for 2 weeks. Colonies were fixed with methanol and stained with 0.1% crystal violet in 20% methanol. Anchorage-independent growth assay were performed in 24-well plates by suspending 1 Â 10 3 transfected cells per well in 0.3% low melting temperature agarose (Sigma) on a 0.5% agarose base layer, both of which contained growth medium. Two weeks later, colonies were visualized by staining with 0.005% crystal violet. Triplicate wells were prepared for each transfectant and the experiment was repeated twice.
Luciferase assay
To verify the precise target of miRNAs, the pMIR-REPORT system (Applied Biosystems) was applied. Briefly, 55-mer double-stranded oligonucleotides containing the predicted miRNA binding sites in AEG-1 were synthesized and ligated between the SpeI and HindIII restriction sites of the pMIR-REPORT Luciferase vector to establish the pLUC-AEG-1 vector. As a control, the pLUC-mutAEG-1 plasmid was also prepared by the same method, except for the synthesized oligonucleotides containing corresponding mutated nucleotides in the seed-match sequence for miR-375. The mutated scrambling sequences were prepared by the online tool in the website http://www.genscript.com/ssl-bin/app/scramble. Synthesized sequences are listed in the Supplementary Table  S2 . In 96-well plates, HepG2 cells were cotransfected with 0.1 mg of pLUC-AEG-1 or pLUC-mutAEG-1, 0.01 mg of pMIR-REPORT b-gal plasmid served as an internal transfection efficiency control, and pre-miR-375 or pre-miR-NC with a 50 nM final concentration. At 24 h after transfection, luciferase and b-galactosidase activities were measured using the DualLight System (Applied Biosystems).
SYBR Green qRT-PCR
HepG2 cells were harvested for RNA extraction 48 h after transfection. The First Strand cDNA Synthesis Kit (Fermentas, Burlington, VT, USA) was applied to synthesize the first strand cDNA followed by real-time PCR using the Platinum SYBR Green qPCR SuperMix UDG reagent (Invitrogen) according to the manufacturer's instruction. GAPDH RNA was used as a control. The primer sequences are listed in Supplementary Table S3 .
Western blot analysis HepG2 cells were harvested for protein extraction 48 h after transfection. Protein lysates were separated by 10% SDS-polyacrylamide gel electrophoresis and then electrophoretically transferred to polyvinylidene fluoride membranes. After blocking, membranes were incubated with primary antibodies overnight at 4 1C and then with secondary antibodies for 1 h in room temperature. Band signals were visualized using an enhanced chemiluminescence kit (Pierce, Minneapolis, MN, USA) and analyzed by Quantity-One software (Bio-Rad, Hercules, CA, USA). The following antibodies were used: anti-AEG-1 (13860-1-AP, Protein Tech, Chicago, IL, USA), anti-b-actin (sc-47778, Santa Cruz, Santa Cruz, CA, USA), goat anti-mouse IgG-horseradish peroxidase (sc-2005, Santa Cruz) and goat anti-rabbit IgG-horseradish peroxidase (sc-2004, Santa Cruz) .
Animal experiments BALB/c athymic nude mice (male, 4-6-weeks old and 16-20 g) were purchased from Hubei Research Center of Laboratory Animal (Wuhan, China) and bred at pathogen-free conditions in Animal Center of Tongji Hospital. All animal experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals of Tongji Hospital. To establish hepatoma xenograft model, 4 Â 10 6 HepG2 cells were suspended in 100 ml phosphate-buffered saline and inoculated subcutaneously into the flanks of nude mice. After 8 days, the transplanted nude mice were randomly divided into two groups (n ¼ 8 each). Chol-miR-375 or NC (Chol-miR-NC) (RiboBio Co., Ltd, Guangzhou, China) was directly injected into the implanted tumor at the dose of 1 nmol (in 20 ml phosphate-buffered saline) per mouse every 4 days for seven times. Tumor volume (V) was monitored by measuring the length (L) and width (W) with vernier caliper and calculated with the formula V ¼ (L Â W 2 ) Â 0.5.
Immunohistochemistry
Resected tumor tissues were fixed in 4% paraformaldehyde, embedded in paraffin, cut into 4 mm and mounted on polylysinecoated slides. Some of the sections were stained with haematoxylin and eosin following standard procedures. For Ki67 detection, the sections were deparaffinized in xylene, rehydrated in gradient alcohol and treated with 0.3% H 2 O 2 for 15 min to quenched endogenous peroxidase activity. Antigen retrieval was performed by permeation in 10 mM citric acid buffer (pH6.0) in a microwave oven for 15 min. After blocking with 2.5% normal horse serum (Vector Laboratories, Burlingame, CA, USA) for 20 min at room temperature, the sections were incubated at 4 1C overnight in a humidity chamber with Ki67 antibody (ab15580, Abcam, Cambridge, MA, USA). The biotinylated universal secondary antibody and VECTASTAIN elite ABC reagent (Vector Laboratories) was used according to the protocols provided by the manufacturer. Subsequently, the sections were incubated with diaminobenzidine as the final chromogen and counterstained with hematoxylin. A no primary antibody control was used to rule out non-specific binding.
Statistical analysis
All data are expressed as mean ± s.e. from three separate experiments performed in triplicate except otherwise noted. The differences between groups were analyzed by Student's t test and Po0.05 was considered to be statistically significant.
